Kapruvia

Difelikefalin, the active ingredient in Kapruvia, is a kappa opioid receptor agonist presented as an intravenous injection for intravenous use. It is indicated to reduce the intense itch experienced by patients with chronic kidney disease undergoing hemodialysis.

GNH USA supplies Kapruvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to EU GMP standards and provides cold‑chain logistics to ensure product integrity during global shipment. Customers receive comprehensive regulatory documentation and support for import clearance.

Kapruvia (difelikefalin) acts on peripheral kappa‑opioid receptors to alleviate itch in renal disease.

- Chronic kidney disease‑associated pruritus: reduces intensity of itch in hemodialysis patients, improving comfort and sleep quality.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Diarrhea: loose stools occurring after administration. - Headache: transient cranial discomfort. - Injection site erythema: redness at the infusion site.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure requiring monitoring. - Severe hypersensitivity reactions: including rash, swelling, or anaphylaxis. - Respiratory depression: reduced breathing effort, especially when combined with other depressants.

Before initiating therapy, clinicians should consider several safety measures. - Monitor renal function: assess kidney status regularly. - Assess for hypersensitivity: inquire about prior allergic reactions to peptide drugs. - Use cautiously in cardiovascular instability: patients with low blood pressure may be at higher risk. - Avoid in known kappa‑opioid receptor hypersensitivity: contraindicated if prior severe reaction. - Adjust when co‑administered with CNS depressants: monitor for enhanced sedation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Difelikefalin may interact with other medications that affect the central nervous system or opioid pathways.

Major Interactions (Avoid): - Opioid agonists: additive opioid effects may increase risk of respiratory depression. - CNS depressants (e.g., benzodiazepines): enhanced sedation and respiratory compromise.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors: potential increase in exposure despite limited metabolism. - CYP3A4 inducers: possible reduction in plasma levels. - Antihistamines: may mask early signs of hypersensitivity.